-+ 0.00%
-+ 0.00%
-+ 0.00%

Keymed Biosciences licenses Stapokibart marketing, sales rights in 18 Southeast and Central Asia markets to Aeira

PUBT·09/02/2026 13:04:28
Listen to the news
Keymed Biosciences licenses Stapokibart marketing, sales rights in 18 Southeast and Central Asia markets to Aeira
  • Keymed entered an exclusive licensing deal with Aeira to register and commercialize Stapokibart injection across 18 Southeast and Central Asian markets.
  • Aeira will lead regulatory filings, market access, commercialization in the licensed territory; Keymed will manufacture and supply the product.
  • Consideration includes an upfront payment, regulatory and commercial milestones, royalties up to a high double-digit % of net sales.
  • Stapokibart is an IL-4Rα antibody marketed in China as Kangyueda, with approvals since 2024-2025 for three allergic inflammation indications.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keymed Biosciences Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260902-12317038), on September 02, 2026, and is solely responsible for the information contained therein.